latest news releases from the newsroom
The Four Month Stockwinners.com Options Portfolio Doubles
AUSTIN, Texas, Jan. 10, 2003 (PRIMEZONE) -- The following is an investment opinion issued by Stockwinners.com. Selections featured in recent Stockwinners.com http://www.STOCKWINNERS.com Option Picks postings registered an average short-term gain of 105 percent. In the four months ending January 3rd, the equities research firm addressed the upward price potential of 340 publicly traded stock options. On average, the entire group was up 105 percent in eight days. The postings included two hundred three calls and one hundred thirty-seven puts.
The Recent Stockwinners.com Momentum Portfolio Registers a Short-Term Eighteen Percent Gain; Options Portfolio Doubles
AUSTIN, Texas, Jan. 10, 2003 (PRIMEZONE) -- The following is an investment opinion issued by Stockwinners.com. Momentum picks featured in recent Stockwinners.com http://www.STOCKWINNERS.com E-mail alerts registered an average short-term gain of 18 percent. The equities research firm addressed the upward price potential of forty-six publicly traded stocks, in alerts issued over the four months ending January 3rd. Nearly two-thirds of the selections generated double digit gains. On average, the entire group was up 18 percent in eighteen days.
Custos: ASG Dispute Decided
STOCKHOLM, Sweden, January 10, 2003 (PRIMEZONE) -- Custos (Other OTC:CUSTF): In 1999 Regular Capital Inc ("Regular") -- which is wholly owned by the Swedish Post Office -- tried to prevent Custos to sell its shares in ASG to the Deutsche Post subsidiary Danzas Sweden AB, ("Danzas"). Regular argued that there was a Shareholders Agreement between the parties. After this question had been tried by the District Court as well as the Appellate Court, both of which dismissed Regulars requests, Custos finalised the transfer of the shares in ASG to Danzas. Subsequently Regular initiated arbitration against Custos. The Arbitral Tribunal rendered an award in August 2000 and declared that Regular's request should be dismissed. The Tribunal concluded that there was no agreement between Regular and Custos, which Custos -- in the opinion of Regular -- could have violated. Regular appealed the Arbitration Award to the Svea Court of Appeal.
All patients in Diamyd's diabetes study included
STOCKHOLM, Sweden, Jan. 10, 2003 (PRIMEZONE) -- Diamyd Medical (SSE:DIAMb) is developing a GAD vaccine for insulin-dependent diabetes. The company reports that patient recruitment has been concluded, that all the patients have now received two vaccinations and that no negative safety indications have been reported for the vaccine so far.
This Week on MoneyTV, 1/10
LOS ANGELES, Jan. 10, 2003 (PRIMEZONE) -- MoneyTV is the nationally syndicated television program all about money, profiling emerging-growth companies (http://www.moneytv.net), featuring informative interviews with the CEOs, insights into their operations and outlooks for their futures.